medrol dosepak

Phase 2Small molecule

EEmory University

medrol dosepak is one of 3 small molecule programs targeting Opioid Consumption. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Opioid ConsumptionRecruiting

Opioid ConsumptionPhase 2

Recruiting

Competition

Competitive Landscape

3 competitors in Opioid Consumption

#DrugCompanyPhaseTrials

Hydrocodone

MM.D. Anderson Cancer Center

Phase 2

1 2

medrol dosepak

EEmory University

Phase 2

1 3

Horizant

AAzurity Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Opioid Consumption

NCT06780202

Clinical

Trials by Indication[1]

Opioid Consumption1 trial

Assessment of Medrol Dosepak to Reduce Opioid Consumption in Foot and Ankle Surgical Patients

Recruiting·EEmory University·Phase 2·NCT06780202·180 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for medrol dosepak. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — medrol dosepak compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for medrol dosepak. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Emory University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: EEmory University

medrol dosepak

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Opioid Consumption1 trial

References

Drug Info

Quick Facts

Related News